Ad
related to: editas medicine stock forecast
Search results
Results from the WOW.Com Content Network
Editas (EDIT) delivered earnings and revenue surprises of 6.90% and 99.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
The average of price targets set by Wall Street analysts indicates a potential upside of 64.9% in Editas (EDIT). While the effectiveness of this highly sought-after metric is questionable, the ...
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
Editas Medicine was originally founded with the name "Gengine, Inc." in September 2013 by Feng Zhang of the Broad Institute, Jennifer Doudna of the University of California, Berkeley, [7] and George Church, David Liu, and J. Keith Joung of Harvard University, with funding from Third Rock Ventures, Polaris Partners and Flagship Ventures; the name was changed to the current "Editas Medicine" two ...
While not a mind-blowing move, it is good to see that the Editas Medicine, Inc. (NASDAQ:EDIT) shar... Did Changing Sentiment Drive Editas Medicine's (NASDAQ:EDIT) Share Price Down By 27%? Skip to ...
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). We reversed our ...
For premium support please call: 800-290-4726 more ways to reach us
Ad
related to: editas medicine stock forecast